Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes
- 257 Downloads
A minority of patients with chronic myeloproliferative disease have constitutive activation of the gene for PDGFRβ; this is usually caused by t(5;12)(q33;p13) translocation associated with a TEL-PDGFRβ fusion gene encoding for a tyrosine kinase receptor which can be inhibited by imatinib. Several reports [1, 2, 3] have suggested that imatinib can affect fasting glucose (FG) level in CML or gastrointestinal stromal tumors (GIST) patients with type II diabetes. Here, we report a patient with TEL-PDGFRβ rearrangement affected by concomitant type 1 diabetes who was treated with imatinib at 400 mg daily and experienced symptomatic FG reduction requiring insulin dose decrease.
A 27-year-old male referred to our institute for asymptomatic isolated leukocytosis (35 × 109/l). While peripheral blood molecular evaluation for BCR-ABL rearrangement was negative, conventional cytogenetic analysis showed a t(5;12)(q33;q13) in 13 out of 22 metaphases analyzed. Qualitative molecular...
KeywordsImatinib Gastrointestinal Stromal Tumor Imatinib Therapy Imatinib Treatment Symptomatic Hypoglycemia
- 2.Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ (2011) Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice. J Oncol Pharm Pract 17:197–202PubMedCrossRefGoogle Scholar
- 8.Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC (2010) Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 95:3763–3767PubMedCrossRefGoogle Scholar